|
Theravance, Inc. - Company Profile Snapshot
| Company Profile: |
Theravance, Inc. |
| Ticker: |
THRX |
| Exchanges: |
NAS |
| 2008 Sales: |
23,096,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED STATES |
| Employees: |
191 |
Business Description
Theravance, Inc.. The Group's principal activity is that of a biopharmaceutical company with a pipeline of internally discovered product candidates. It focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Its programs include: telavancin for the treatment of serious Gram-positive bacterial infections with Astellas Pharma Inc. and Horizon program and the Bifunctional Muscarinic Antagonist-beta2 Agonist program with GlaxoSmithKline PLC.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
